EdgarLookup

Evommune, Inc. — Quarterly Financials

Quarterly figures from SEC EDGAR XBRL filings (10-Q)

These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Evommune, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.

Overview All Filings Annual Quarterly Insiders

Revenue — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 $10.00M Dec 11, 2025
Q3 2025 Sep 30, 2024 $7.00M Dec 11, 2025

Net Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($12.48M) Dec 11, 2025
Q3 2025 Sep 30, 2024 ($15.92M) Dec 11, 2025

Operating Income — By Quarter

Quarter Fiscal Year Period End Value Filed
Q3 2025 Sep 30, 2025 ($13.33M) Dec 11, 2025
Q3 2025 Sep 30, 2024 ($16.52M) Dec 11, 2025